Study of Carboplatin, Epirubicin, and Docetaxel for Ovarian Cancer
Author Information
Author(s): O'Neill V J, Kaye S B, Reed N S, Paul J, Davis J A, Vasey P A
Primary Institution: Cancer Research UK Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK
Hypothesis
Does adding epirubicin to the carboplatin-docetaxel combination provide additional benefits in treating advanced epithelial ovarian cancer?
Conclusion
The combination of carboplatin, epirubicin, and docetaxel shows activity in patients with ovarian cancer, but toxicity-induced dose reductions and delays may limit its utility.
Supporting Evidence
- The overall response rate was 36%, and 62% were CA125 responders.
- Grade IV neutropenia was observed in 18 patients (86%).
- Significant non-haematological toxicity was unusual, and treatment was generally well tolerated.
Takeaway
Doctors tested a new combination of three cancer drugs to see if they could help women with advanced ovarian cancer. They found it worked but caused some side effects.
Methodology
Twenty-one patients with advanced epithelial ovarian cancer were treated with a combination of carboplatin, epirubicin, and docetaxel in four dose cohorts.
Potential Biases
Potential bias due to the small sample size and lack of a control group.
Limitations
The study had a small sample size and was primarily focused on toxicity and feasibility rather than efficacy.
Participant Demographics
Patients were women over 18 years old with histologically verified epithelial ovarian cancer, primarily FIGO stages III and IV.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI=6–18 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website